© 2019  by Bria Fund ™ Supporters for FIP Research

  • Black Facebook Icon
  • Black Twitter Icon

October 3, 2018

Winn's Weekly Feline Research Byte

The Latest News on FIP Research, the Bria Fund and Winn Feline Foundation

A recent media release announced licensure and commercial development of GC376, an antiviral FIP drug demonstrated to cure some cats with FIP. The research on the drug was coordinated between Dr. Yunjeong Kim of Kansas State University and Dr. Niels Pedersen of University of California-Davis. 

Because of the research results, the Kansas State University of Commercialization coordinated a licensing agreement with Anivive Lifesciences, a California company with proprietary software able to advance discovery and development of new pet medications. While GC376 is still several years from release, if FDA app...

Please reload

RSS Feed
RSS Subscribe
Featured Posts

Contaminated Generic Drugs

1/7
Please reload

Categories
Please reload

Search By Tags
Please reload

Archive
Please reload